IGFN1

Overview

IGFN1 (Immunoglobulin-like and Fibronectin type III domain-containing protein 1) encodes a large structural protein. In cancer genomics, IGFN1 has been identified as part of a metastatic-enrichment gene signature in breast cancer, with mutations occurring more frequently in metastatic than in early-stage disease.

Alterations observed in the corpus

  • IGFN1 identified among eight genes significantly more mutated in metastatic breast cancer (mBC) vs early breast cancer (eBC) at FDR<0.01; part of the 8-gene metastatic-enrichment signature associated with a 2-fold higher death hazard (HR=1.97, p=0.001) PMID:28027327.

Cancer types (linked)

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • No direct therapeutic target identified; IGFN1 is a component of a prognostic multi-gene signature rather than a druggable target PMID:28027327.

Open questions

  • Whether IGFN1 mutations are drivers of metastatic progression or passenger events co-selected under endocrine therapy pressure requires further functional validation PMID:28027327.
  • The 8-gene metastatic-enrichment survival association was not corrected for mutational load or signature contribution, limiting causal inference PMID:28027327.

Sources

This page was processed by crosslinker on 2026-05-14.